Clinical trials: System Sclerosis
Secondary Progressive Multiple Sclerosis
Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
The purpose of this study is to compare expanded disability status scale, annualized relapse rate, Gad-enhanced brain lesions, and side effects after administration of rituximab and glatiramer acetate among patients with active…
- Trial name
- NCT03315923
- Testing
- Rituximab, Glatiramer Acetate
- Where
- Iran
- Volunteers
- 84 people
- Sponsor
- Isfahan University of Medical Sciences
Relapsing Forms of Multiple Sclerosis
Plegridy Observational Program
The primary objectives of the study are to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to assess the overall long-term…
- Trial name
- POP (NCT02230969)
- Testing
- peginterferon beta-1a
- Where
- 152 sites in United States, Australia and 12 more
- Volunteers
- 1,208 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis
The purpose of this study is to determine whether nebulized RNS60 is effective in the treatment of amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT02988297
- Testing
- RNS60
- Sponsor
- Revalesio Corporation
Neurologic Disorder, Neurologic Diseases
Functional Outcomes and Control Using Synchron BCI - Australia
Functional Outcomes and Control Using Synchron BCI - Australia (FOCUS-AUS)
- Conditions
- Neurologic Disorder, Neurologic Diseases, MND (Motor Neurone DIsease), Motor Neuron Disease
- Trial name
- FOCUS-AUS (NCT07533903)
- Testing
- Stentrode
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Synchron, Inc.
Multiple Sclerosis
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration…
- Trial name
- FREVIVA (NCT06141486)
- Testing
- Frexalimab, MRI contrast-enhancing agents
- Where
- 311 sites in United States, Argentina and 25 more
- Volunteers
- 943 people
- Sponsor
- Sanofi
Healthy, Prodromal Alzheimer's Disease
Exploring the Gut-Brain Axis in Ageing and Neurodegeneration
Neurodegenerative diseases are a major health concern due to their growing societal implications and economic costs. The identification of early markers of pathogenic mechanisms is one of the current main challenges.
- Conditions
- Healthy, Prodromal Alzheimer's Disease, Parkinson Disease, Multiple Sclerosis
- Trial name
- GutBrain (NCT05934188)
- Testing
- Magnetic Resonance Imaging, Neuropsychological protocol, Eating habits
- Where
- 3 sites in Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- IRCCS San Camillo, Venezia, Italy
Multiple Sclerosis, Relapsing Remitting
Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
The rationale of this study is to assess the safety profile, efficacy and adherence to Rebif® New Formulation in real life settings with a multinational approach, as well as the impact of this improved formulation (with regards…
- Trial name
- STAR (NCT01080027)
- Testing
- Rebif® New Formulation
- Where
- Greece
- Volunteers
- 254 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Investigation of GM Pathology Using Ultra High Field (7T) MRI Scanner
Magnetization transfer imaging is a magnetic resonance technique that has been used over the last few years, and known for its ability to detect abnormalities that can be difficult to detect by conventional MRI techniques.
- Trial name
- NCT01805986
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Multiple Sclerosis
Local Vibration in Multiple Sclerosis Patients
Gastrocnemius spasticity is one of the main complaints in Multiple Sclerosis patients.Local muscle vibration is a method used for spasticity inhibition.
- Trial name
- NCT04192786
- Testing
- Standard physiotherapy program+50 Hz local vibration, Standard physiotherapy program+100 Hz local vibration, Standard physiotherapy program
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Hacettepe University
Multiple Sclerosis
Improving New Learning and Memory in Multiple Sclerosis
The current study is a double-blind, placebo-control randomized clinical trial examining the efficacy of memory retraining in Multiple Sclerosis (MS).
- Trial name
- NCT00166283
- Testing
- memory retraining exercises
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Kessler Foundation
Neurogenic Bowel (Disorder), Fecal Constipation
Comparing Transanal Irrigation With Navina Smart vs. Standard Bowel Care in Patients With Multiple Sclerosis
A randomized, superiority, controlled, interventional, prospective, multicentre, post-market study of TAI with Navina™ Smart versus Standard Bowel Care performed in a population of 92 subjects suffering from Multiple Sclerosis…
- Conditions
- Neurogenic Bowel (Disorder), Fecal Constipation, Fecal Incontinence, Multiple Sclerosis
- Trial name
- NCT04707976
- Testing
- Navina Smart, Standard Bowel Care
- Where
- 9 sites in Denmark, France and 4 more
- Volunteers
- 92 people
- Sponsor
- Wellspect HealthCare
Amyotrophic Lateral Sclerosis
RAPA-501 Therapy for ALS
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
- Trial name
- NCT04220190
- Testing
- RAPA-501 Autologous T stem cells
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Rapa Therapeutics LLC
Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis
Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) who are treated with dimethyl fumarate (DMF) as their…
- Trial name
- IMPROVE (NCT02323269)
- Testing
- dimethyl fumarate
- Where
- 10 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod
Data on fingolimod effects on NK cells are so far conflicting. A longitudinal study on fingolimod treated kidney transplant patients showed that NK cells were not influenced in any of the treatment groups.
- Trial name
- NCT01790269
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Charite University, Berlin, Germany
Multiple Sclerosis, Relapsing-Remitting
COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS
A phase IV, observational, survey-based study to measure compliance with Avonex® PS therapy in patients with Relapsing-Remitting Multiple Sclerosis, and to compare persistence on therapy 22 months after initial prescription of…
- Trial name
- COMPASS (NCT00675883)
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Biogen
Autoimmune Disease
Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study
Autoimmune diseases may involve nearly any organ and are characterized by abnormal activation or response of certain cells. Evidence suggests that farm work, exposure to silica from farming activities and exposure to pesticides…
- Trial name
- NCT00341198
- Where
- 3 sites in United States
- Volunteers
- 700 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Amyotrophic Lateral Sclerosis (ALS), Autoantibody
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)
10-20% of patients with ALS have anti-NRIP autoantibody and the titer of anti-NRIP autoantibody is correlated with motor functional decline and mortality in ALS.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Autoantibody, Plasmapheresis
- Trial name
- PALADIN2 (NCT07726563)
- Testing
- plasmapheresis
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder
Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases
This is an uncontrolled, prospective, observational cohort study to assess the function of meningeal lymphatic drainage and dynamics of immune cells in patients with relapsing multiple sclerosis (RMS) or Neuromyelitis optica…
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Demyelinating Diseases of the Central Nervous System
- Trial name
- OMNISCIENCE (NCT05414487)
- Testing
- Ofatumumab
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Tianjin Medical University General Hospital
Multiple Sclerosis, Fatigue
Pilot Study for the Evaluation of the More Stamina in Persons With Multiple Sclerosis
The overall study aims are to explore the feasibility, acceptability, and usability of More Stamina, a mobile app for fatigue self-management for persons with MS.
- Conditions
- Multiple Sclerosis, Fatigue, Chronic Conditions, Multiple
- Trial name
- NCT04244214
- Testing
- More Stamina
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Hospital Italiano de Buenos Aires
Multiple Sclerosis, Muscle Spasticity
Intermittent Theta-Burst Stimulation for Lower-Limb Spasticity and Pain in Multiple Sclerosis
Spasticity and neuropathic pain are frequent and disabling symptoms of multiple sclerosis. Intermittent theta-burst stimulation (iTBS) is a non-invasive neuromodulation technique that may modulate cortical and corticospinal…
- Conditions
- Multiple Sclerosis, Muscle Spasticity, Neuropathic Pain
- Trial name
- TMS-SPASMS (NCT07786506)
- Testing
- Active Intermittent Theta-Burst Stimulation (iTBS)
- Where
- Slovakia
- Volunteers
- 40 people
- Sponsor
- Comenius University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.